Brigatinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
BRIGATINIB: Evaluation Report — Insufficient Evidence Pack Data
One-Sentence Summary
BRIGATINIB (DrugBank ID: DB12267) is a compound for which the current Evidence Pack contains no original indication data, no TxGNN-predicted new indications, and no safety profile. A structured drug repurposing evaluation cannot be completed at this stage. The drug is currently not marketed in Germany, and all downstream assessment steps are blocked until critical data gaps are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No predictions or empirical studies in current pack) |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Conclusion and Next Steps
Decision: Hold
Rationale: All five evaluation pillars — original indication, mechanism of action, TxGNN repurposing prediction, regulatory footprint, and safety profile — are either empty or blocked by unresolved data gaps. There is currently no valid repurposing hypothesis to assess, and the Blocking-severity safety gap (DG001) prevents entry into even the initial S1 safety screening step.
To proceed, the following is needed:
- TxGNN prediction run (Critical): The
predicted_indicationsarray is empty. A complete TxGNN inference run against the disease knowledge graph must be executed before any repurposing opportunity can be identified or ranked. - Safety profile (Blocking — DG001): Package insert warnings and contraindications are absent. Download and parse the TFDA package insert PDF to unlock the S1 safety screening gate.
- Mechanism of action (High — DG002): MOA data is unavailable. Retrieve pharmacological target and pathway information via DrugBank API (DB12267) to support mechanistic plausibility analysis.
- Original indication data: No approved indications are recorded in the pack. Cross-verify against TFDA, EMA, and DrugBank product listings to establish the clinical baseline.
- Drug interaction data: The DDI query returned zero results. Validate completeness via the DrugBank interaction database before assuming an absence of interactions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.